Edition:
United Kingdom

Santhera Pharmaceuticals Holding AG (SANN.S)

SANN.S on Swiss Exchange

14.74CHF
21 Sep 2018
Change (% chg)

CHF-0.42 (-2.77%)
Prev Close
CHF15.16
Open
CHF15.00
Day's High
CHF15.28
Day's Low
CHF14.74
Volume
9,985
Avg. Vol
11,086
52-wk High
CHF41.15
52-wk Low
CHF14.52

Select another date:

Tue, Sep 4 2018

BRIEF-Santhera Hopes for Good News to Lift Shares, Pave Way For Capital Hike

* SAYS EXPECTS 50 MILLION SFR SALES OF RAXONE WITHIN 2-3 YEARS‍​

Santhera lifts forecast amid cash burn, trial setbacks

ZURICH, Sept 4 Santhera lifted its full-year 2018 sales forecast slightly but quickly drew down cash reserves in the first half, as the Swiss drugmaker continued efforts to make a success of its main drug despite regulatory and trial setbacks.

BRIEF-Santhera Pharmaceuticals Holding H1 Net Result Of CHF -27.4 Mln

* 1H 2018 SALES OF CHF 16.0 MILLION, INCREASE OF 48% COMPARED TO 1H 2017

BRIEF-Santhera: MHRA Renews Early Access Option For Raxone For Duchenne

* UK'S MHRA RENEWS EARLY ACCESS TO MEDICINES SCHEME SCIENTIFIC OPINION FOR SANTHERA'S RAXONE® (IDEBENONE) IN DUCHENNE MUSCULAR DYSTROPHY Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Santhera Submits NDA In South Korea For Raxone For The Treatment Of LHON

* SANTHERA SUBMITS NDA IN SOUTH KOREA FOR RAXONE® FOR THE TREATMENT OF LHON

BRIEF-Santhera Successfully Completes First Clinical Trial With Omigapil In Patients With Congenital Muscular Dystrophy ‍​

* SUCCESSFUL COMPLETION OF FIRST CLINICAL TRIAL WITH OMIGAPIL IN PATIENTS WITH CONGENITAL MUSCULAR DYSTROPHY ‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: